Shield Therapeutics (STU:1JS) Buyback Yield %: -13.69 (As of Jun. 30, 2026)


What is Shield Therapeutics Buyback Yield %?

Shield Therapeutics STU:1JS Buyback Yield % is -13.69 as of Jun. 30, 2026. The stock has 5 warning signs investors should review. Among 292 Drug Manufacturers companies, Shield Therapeutics ranks worse than 81.16% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Shield Therapeutics's current buyback yield was -13.69%.

Shield Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Shield Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics Buyback Yield % Chart

Shield Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.51 -0.03 -40.84 -0.45 -8.69

Shield Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.43 -36.29 -0.34 -22.82 -8.49

STU:1JS vs ZTS, UTHR, VTRS: Buyback Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics Buyback Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's Buyback Yield % falls into.


Shield Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Shield Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 10.209) / 117.4624
=-8.69%

Shield Therapeutics's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 10.209) / 117.4624
=-8.69%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -13.69 mean?
Shield Therapeutics (STU:1JS) has a Buyback Yield % of -13.69 as of Jun. 30, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Shield Therapeutics and its competitors. According to the industry distribution chart, Shield Therapeutics ranks #237 out of 292 companies in the Drug Manufacturers industry, placing it in the top 81.2%.
Is Shield Therapeutics' Buyback Yield % too high?
Shield Therapeutics' current Buyback Yield % is -13.69. Based on the distribution chart, Shield Therapeutics ranks #237 out of 292 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Shield Therapeutics' Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shield Therapeutics ranks #237 out of 292 companies for Buyback Yield %. This places Shield Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Shield Therapeutics and its competitors. Shield Therapeutics's current Buyback Yield % is -13.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.07 — trading 32% below its estimated fair value. The current Buyback Yield % is -13.69. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current Buyback Yield % is -13.69 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shield Therapeutics Business Description

Other Exchanges SHIEF:USASTX:UK1JS:Germany
Address Gateshead Quays, Northern Design Centre, Baltic Business Quarter, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.